Literature DB >> 31932366

Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?

A Kontou1, K Sarafidis1, O Begou2,3, H G Gika4,3, A Tsiligiannis5, K Ogungbenro6, A Dokoumetzidis5, E Agakidou1, E Roilides7.   

Abstract

Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the currently recommended dosing regimen in term and preterm neonates. By using an optimal design approach, a prospective PK study was designed and implemented in 60 neonates with postmenstrual ages (PMA) of 26 to 43 weeks. A loading dose of 16 mg/kg was administered at day 1, followed by a maintenance dose of 8 mg/kg daily. Plasma concentrations were quantified by high-pressure liquid chromatography-mass spectrometry. Population PK (popPK) analysis was performed using NONMEM software. Monte-Carlo (MC) simulations were performed to evaluate currently recommended dosing based on a pharmacodynamic index of area under the concentration-time curve (AUC)/MIC ratio of ≥400. A two-compartment model with linear elimination best described the data by the following equations: clearance (CL) = 0.0227 × (weight [wt]/1,765)0.75 × (estimated creatinine clearance [eCRCL]/22)0.672, central compartment volume of distribution (V1) = 0.283 (wt/1,765), intercompartmental clearance (Q) = 0.151 (wt/1,765)0.75, and peripheral compartment volume (V2) = 0.541 (wt/1,765). The interindividual variability estimates for CL, V1, and V2 were 36.5%, 45.7%, and 51.4%, respectively. Current weight (wt) and estimated creatinine clearance (eCRCL) significantly explained the observed variability. MC simulation demonstrated that, with the current dosing regimen, an AUC/MIC ratio of ≥400 was reached by only 68.5% of neonates with wt of <1 kg when the MIC was equal to 1 mg/kg, versus 82.2%, 89.7%, and 92.7% of neonates with wt of 1 to <2, 2 to <3, or ≥3 kg, respectively. Augmentation of a maintenance dose up to 10 or 11 mg/kg for preterm neonates with wt of 1 to <2 or <1 kg, respectively, increases the probability of reaching the therapeutic target; the recommended doses seem to be adequate for neonates with wt of ≥2 kg. Teicoplanin PK are variable in neonates, with wt and eCRCL having the most significant impact. Neonates with wt of <2 kg need higher doses, especially for Staphylococcus spp. with an MIC value of ≥1 mg/liter.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Monte Carlo simulation; neonates; population pharmacokinetics; premature neonates; preterm neonates; teicoplanin

Mesh:

Substances:

Year:  2020        PMID: 31932366      PMCID: PMC7179285          DOI: 10.1128/AAC.01971-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method.

Authors:  Karel Allegaert; Maike Kuppens; Djalila Mekahli; Elena Levtchenko; Florent Vanstapel; Christine Vanhole; John N van den Anker
Journal:  J Matern Fetal Neonatal Med       Date:  2012-02-14

2.  A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models.

Authors:  Ivelina Gueorguieva; Kayode Ogungbenro; Gordon Graham; Sophie Glatt; Leon Aarons
Journal:  Comput Methods Programs Biomed       Date:  2007-02-09       Impact factor: 5.428

Review 3.  Mechanism-based concepts of size and maturity in pharmacokinetics.

Authors:  B J Anderson; N H G Holford
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 4.  Application of optimal design methodologies in clinical pharmacology experiments.

Authors:  Kayode Ogungbenro; Aristides Dokoumetzidis; Leon Aarons
Journal:  Pharm Stat       Date:  2009 Jul-Sep       Impact factor: 1.894

5.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

Review 6.  Optimal design of pharmacokinetic studies.

Authors:  Leon Aarons; Kayode Ogungbenro
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-01-20       Impact factor: 4.080

Review 7.  Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies.

Authors:  Jessica K Roberts; Chris Stockmann; Alfred Balch; Tian Yu; Robert M Ward; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Paediatr Anaesth       Date:  2015-01-09       Impact factor: 2.556

8.  Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units.

Authors:  C P Hornik; P Fort; R H Clark; K Watt; D K Benjamin; P B Smith; P Manzoni; E Jacqz-Aigrain; F Kaguelidou; M Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2012-05       Impact factor: 2.079

9.  A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth.

Authors:  L P Brion; A R Fleischman; C McCarton; G J Schwartz
Journal:  J Pediatr       Date:  1986-10       Impact factor: 4.406

10.  Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection.

Authors:  Diogo Diniz Gomes Bugano; Alexandre Biasi Cavalcanti; Anderson Roman Goncalves; Claudia Salvini de Almeida; Eliézer Silva
Journal:  Einstein (Sao Paulo)       Date:  2011-09
View more
  1 in total

1.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.